Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
This study is currently recruiting participants.
(see Contacts and Locations)
Verified April 2017 by OHSU Knight Cancer Institute
Sponsor:
OHSU Knight Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Edward Neuwelt, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT00075387
First received: January 9, 2004
Last updated: April 19, 2017
Last verified: April 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This randomized phase II trial studies how well giving combination chemotherapy with or without sodium thiosulfate works in preventing low platelet count while treating patients with malignant brain tumors. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sodium thiosulfate may prevent low platelet counts in patients receiving chemotherapy. It is not yet known whether combination chemotherapy is more effective with or without sodium thiosulfate in preventing low platelet count during treatment for brain tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Glioma |
Drug: Carboplatin Drug: Cyclophosphamide Drug: Etoposide Phosphate Other: Quality-of-Life Assessment Drug: Sodium Thiosulfate |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Investigator Primary Purpose: Supportive Care |
| Official Title: | Phase II Clinical Trial of Patients With High-Grade Glioma Treated With Intra-Arterial Carboplatin-Based Chemotherapy, Randomized to Treatment With or Without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant Against Severe Thrombocytopenia |
Resource links provided by NLM:
Further study details as provided by OHSU Knight Cancer Institute:
Primary Outcome Measures:
- Rate of platelet toxicities (ie. platelet count less than 20,000), graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 3.0 [ Time Frame: Up to 4 weeks after completion of study treatment ]The Pearson chi-square test will be the primary test to compare rates.
Secondary Outcome Measures:
- Change in hearing levels, if any, at the higher frequencies in the standard testing range (4000 and 8000 Hz), and at higher frequencies above standard testing (9000 to 16000 Hz) based on American Speech-Language-Hearing Association (ASHA) criteria [ Time Frame: Baseline up to 30 days after completion of study treatment ]Descriptive summaries for hearing levels will include means by time and plots of hearing levels by patient over time. The analyses for hearing will include both a time to oto-toxicity (based on ASHA criteria) comparison using the log rank test and a repeated measure analysis of covariance of the actual hearing levels (with baseline hearing levels as the covariate). Separate analyses will be performed for each hearing frequency with no adjustment for multiple comparisons (as these analyses are descriptive in nature).
- Erythrocyte counts [ Time Frame: Up to 30 days after completion of study treatment ]The Pearson chi-square test will be the primary test to compare rates.
- Granulocyte count [ Time Frame: Up to 30 days after completion of study treatment ]The Pearson chi-square test will be the primary test to compare rates.
- Number of dose reductions and transfusions due to platelet toxicity [ Time Frame: Up to 30 days after completion of study treatment ]Analyzed using generalized estimating equations (GEE) and/or a generalized mixed model (for repeated measures analysis of variance [ANOVA]) and the third using mixed model repeated measures ANOVA model.
- Quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 and QLQ-Brain Module (BN)-20 [ Time Frame: Up to 60 days after completion of study treatment ]Summarized by means over time and by plots of values over time for each patient. Quality of life data comparisons between the groups will use repeated measure analysis of covariance (baseline assessment as the covariate).
- Time to disease progression [ Time Frame: Up to 10 years ]Comparisons of time to disease progression will use the log rank test and the Cox proportional hazards model to adjust for potential confounders.
- Time to response [ Time Frame: Up to 10 years ]Descriptive summaries include Kaplan-Meier plots.
- Tumor response (complete response [CR] + partial response [PR] + stable disease [SD]) assessed by neurologic exams, radiographic studies, and steroid dose [ Time Frame: Up to 10 years ]The Pearson chi-square test will be the primary test to compare rates. Comparisons of rates will use the Pearson Chi-square test and logistic regression to adjust for potential confounders.
| Estimated Enrollment: | 60 |
| Study Start Date: | March 2003 |
| Estimated Study Completion Date: | April 2019 |
| Estimated Primary Completion Date: | April 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm I (combination chemotherapy)
Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. |
Drug: Carboplatin
Given IA
Other Names:
Drug: Cyclophosphamide
Given IV
Other Names:
Drug: Etoposide Phosphate
Given IV
Other Name: Etopophos
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
|
|
Experimental: Arm II (combination chemotherapy, sodium thiosulfate)
Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. |
Drug: Carboplatin
Given IA
Other Names:
Drug: Cyclophosphamide
Given IV
Other Names:
Drug: Etoposide Phosphate
Given IV
Other Name: Etopophos
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Drug: Sodium Thiosulfate
Given IV
Other Names:
|
Detailed Description:
PRIMARY OBJECTIVES:
I. Determine the effect of delayed administration of sodium thiosulfate on the rates of platelet toxicity (ie. platelet count less than 20,000), in subjects with high-grade glioma undergoing treatment with carboplatin, cyclophosphamide and etoposide/etoposide phosphate.
SECONDARY OBJECTIVES:
I. Assess tumor response in subjects with high-grade glioma undergoing treatment with carboplatin, cyclophosphamide and etoposide/etoposide phosphate, with or without delayed sodium thiosulfate.
II. Assess the effect of delayed administration of sodium thiosulfate on granulocyte and erythrocyte counts, in subjects undergoing treatment with carboplatin, cyclophosphamide and etoposide/etoposide phosphate.
III. Assess hearing changes, if any, at the higher frequencies in the standard testing range (4000 and 8000 Hertz [Hz]), and at higher frequencies above standard testing (9000 to 16000 Hz).
IV. Assess quality of life in subjects undergoing treatment with carboplatin, cyclophosphamide and etoposide phosphate.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive cyclophosphamide intravenously (IV), etoposide phosphate IV, and carboplatin intra-arterially (IA) over 10 minutes on day 1.
ARM II: Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours after carboplatin.
In both arms, treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects with histologically confirmed high-grade glioma are eligible; diagnosis of high-grade glioma will be made on the basis of needle biopsy, open biopsy, or surgical resection
- Subjects may have had prior focal or systemic radiation or chemotherapy; at least 14 days must have elapsed since radiation treatment and 28 days since prior chemotherapy
- Performance status (Eastern Cooperative Oncology Group [ECOG]) must be less than or equal to 2 (Karnofsky greater than or equal to 50)
- White blood cell count >= 2.5 x 10^3/mm^3
- Absolute granulocyte count >= 1.2 x 10^3/mm^3
- Platelets >= 100 x 10^3/mm^3
- Creatinine < 1.8
- Bilirubin < 2.0
- Baseline aspartate aminotransferase (AST)/alanine aminotransferase (ALT) serum glutamic oxaloacetic transaminase (SGOT)/serum glutamate pyruvate transaminase (SGPT) must be < 2.5 x institutional upper limits of normal
- Subject (or legal guardian) must sign a written informed consent in accordance with institutional guidelines
- Sexually active women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study treatment and for the duration of study treatment; should a female become pregnant or suspect she is pregnant while participating in this study, she should inform the investigator
Exclusion Criteria:
- Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration
- Subjects with uncontrolled (over the last 30 days) clinically significant confounding medical conditions such as congestive heart failure
- Subjects who are pregnant, have a positive serum human chorionic gonadotropin (hCG) or are lactating
- Subjects who have contraindications to carboplatin, cyclophosphamide, etoposide phosphate, or sodium thiosulfate
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00075387
Please refer to this study by its ClinicalTrials.gov identifier: NCT00075387
Locations
| United States, Minnesota | |
| University of Minnesota/Masonic Cancer Center | Recruiting |
| Minneapolis, Minnesota, United States, 55455 | |
| Contact: Matthew A. Hunt 612-624-1452 huntx188@umn.edu | |
| Principal Investigator: Matthew A. Hunt | |
| United States, Ohio | |
| Cleveland Clinic Foundation | Recruiting |
| Cleveland, Ohio, United States, 44195 | |
| Contact: Glen H. Stevens steveng@ccf.org | |
| Principal Investigator: Glen H. Stevens | |
| United States, Oregon | |
| OHSU Knight Cancer Institute | Recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Edward A. Neuwelt 503-494-5626 neuwelte@ohsu.edu | |
| Principal Investigator: Edward A. Neuwelt | |
Sponsors and Collaborators
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Edward Neuwelt | OHSU Knight Cancer Institute |
More Information
| Responsible Party: | Edward Neuwelt, Professor, OHSU Knight Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT00075387 History of Changes |
| Other Study ID Numbers: |
IRB00000922 NCI-2013-00781 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) MR00041590 CR00023930 eIRB #922 CR00018679 ONC-02019-L CR00021317 CR00022743 IRB00000922 ( Other Identifier: OHSU Knight Cancer Institute ) P30CA069533 ( US NIH Grant/Contract Award Number ) |
| Study First Received: | January 9, 2004 |
| Last Updated: | April 19, 2017 |
Additional relevant MeSH terms:
|
Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Etoposide Etoposide phosphate Cyclophosphamide Carboplatin Sodium thiosulfate Antineoplastic Agents, Phytogenic Antineoplastic Agents |
Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Myeloablative Agonists Antidotes Protective Agents Antioxidants Antitubercular Agents |
ClinicalTrials.gov processed this record on May 25, 2017